Pasar al contenido principal

Resultados relacionados

Resultados totales (Incluyendo duplicados): 3
Encontrada(s) 1 página(s)

Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

APP-derived peptides reflect neurodegeneration in frontotemporal dementia

  • Illán-Gala, Ignacio|||0000-0002-5418-2052
  • Pegueroles, Jordi|||0000-0002-3554-2446
  • Vilaplana, Eduard|||0000-0002-1809-8435
  • Montal, Victor|||0000-0002-5714-9282
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Bejanin, Alexandre|||0000-0002-9958-0951
  • Borrego-Écija, Sergi|||0000-0003-2557-0010
  • Sampedro, Frederic|||0000-0002-3933-1355
  • Subirana, Andrea
  • Sánchez-Saudinós, María Belén|||0000-0003-1795-1833
  • Rojas-Garcia, Ricard|||0000-0003-1411-5573
  • Vanderstichele, Hugo
  • Blesa, Rafael|||0000-0003-4026-2884
  • Clarimón, Jordi|||0000-0002-6824-6942
  • Antonell, Anna|||0000-0002-3286-8459
  • Llado Plarrumani, Albert|||0000-0002-5066-4150
  • Sánchez Valle, Raquel|||0000-0001-7750-896X
  • Fortea, Juan|||0000-0002-1340-638X
  • Lleó, Alberto|||0000-0002-2568-5478
Objective: We aimed to investigate the relationship between cerebrospinal fluid levels (CSF) of amyloid precursor protein (APP)-derived peptides related to the amyloidogenic pathway, cortical thickness, neuropsychological performance, and cortical gene expression profiles in frontotemporal lobar degeneration (FTLD)-related syndromes, Alzheimer's disease (AD), and healthy controls. Methods: We included 214 participants with CSF available recruited at two centers: 93 with FTLD-related syndromes, 57 patients with AD, and 64 healthy controls. CSF levels of amyloid β (Aβ)1-42, Aβ1-40, Aβ1-38, and soluble β fragment of APP (sAPPβ) were centrally analyzed. We compared CSF levels of APP-derived peptides between groups and, we studied the correlation between CSF biomarkers, cortical thickness, and domain-specific cognitive composites in each group. Then, we explored the relationship between cortical thickness, CSF levels of APP-derived peptides, and regional gene expression profile using a brain-wide regional gene expression data in combination with gene set enrichment analysis. Results: The CSF levels of Aβ1-40, Aβ1-38, and sAPPβ were lower in the FTLD-related syndromes group than in the AD and healthy controls group. CSF levels of all APP-derived peptides showed a positive correlation with cortical thickness and the executive cognitive composite in the FTLD-related syndromes group but not in the healthy control or AD groups. In the cortical regions where we observed a significant association between cortical thickness and CSF levels of APP-derived peptides, we found a reduced expression of genes related to synaptic function. Interpretation: APP-derived peptides in CSF may reflect FTLD-related neurodegeneration. This observation has important implications as Aβ1-42 levels are considered an indirect biomarker of cerebral amyloidosis.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimer's disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity

  • van der Lee, Sven J.|||0000-0003-1606-8643
  • Conway, Olivia J.
  • Jansen, Iris E.|||0000-0003-1901-8131
  • Carrasquillo, Minerva M.
  • Kleineidam, Luca
  • van den Akker, Erik
  • Hernández, Isabel|||0000-0001-8119-393X
  • Van Eijk, Kristel R.
  • Stringa, Najada|||0000-0001-6350-452X
  • Chen, Jason A.
  • Zettergren, Anna|||0000-0002-7182-8417
  • Andlauer, Till F. M.|||0000-0002-2917-5889
  • Diez-Fairen, Monica|||0000-0003-1882-0309
  • Simón Sánchez, Javier|||0000-0001-5141-5829
  • Lleó, Alberto|||0000-0002-2568-5478
  • Zetterberg, Henrik|||0000-0003-3930-4354
  • Nygaard, Marianne|||0000-0003-0703-2665
  • Blauwendraat, Cornelis|||0000-0001-9358-8111
  • Savage, Jeanne E.
  • Mengel-From, Jonas
  • Moreno-Grau, Sonia
  • Wagner, Michael
  • Fortea, Juan|||0000-0002-1340-638X
  • Keogh, Michael J.
  • Blennow, Kaj|||0000-0002-1890-4193
  • Skoog, Ingmar
  • Friese, Manuel A.
  • Pletnikova, Olga|||0000-0001-6516-4944
  • Zulaica, Miren
  • Lage, Carmen|||0000-0003-1703-121X
  • De Rojas, Itziar|||0000-0002-2148-381X
  • Riedel-Heller, Steffi|||0000-0003-4321-6090
  • Illán-Gala, Ignacio|||0000-0002-5418-2052
  • Wei, Wei
  • Jeune, Bernard
  • Orellana del Río, Adelina|||0000-0002-0204-1944
  • Then Bergh, Florian
  • Wang, Xue
  • Hulsman, Marc|||0000-0002-9889-3606
  • Beker, Nina
  • Tesi, Niccolo|||0000-0002-1413-5091
  • Morris, Christopher M.
  • Indakoetxea, Begoña
  • Collij, Lyduine E.
  • Scherer, Martin
  • Morenas-Rodríguez, Estrella|||0000-0002-7591-6051
  • Ironside, James W.
  • van Berckel, Bart N. M.
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Wiendl, Heinz|||0000-0003-4310-3432
  • Strickland, Samantha L.
  • Pastor, Pau|||0000-0002-7493-8777
  • Rodríguez-Rodríguez, Eloy|||0000-0001-7742-677X
  • Boeve, Bradley
  • Petersen, Ronald C.
  • Ferman, Tanis J.
  • van Gerpen, Jay A.
  • Reinders, Marcel J. T.|||0000-0002-1148-1562
  • Uitti, Ryan J.
  • Tárraga, Lluís|||0000-0002-8423-946X
  • Maier, Wolfgang
  • Dols Icardo, Oriol|||0000-0003-2656-8748
  • Kawalia, Amit
  • Dalmasso, Maria Carolina|||0000-0002-4901-9955
  • Boada, Mercè|||0000-0003-2617-3009
  • Zettl, Uwe K.
  • van Schoor, Natasja M.
  • Beekman, Marian|||0000-0003-0585-6206
  • Allen, Mariet
  • Masliah, Eliezer
  • de Munain, Adolfo López
  • Pantelyat, Alexander
  • Wszolek, Zbigniew K.|||0000-0001-5487-1053
  • Ross, Owen A.|||0000-0003-4813-756X
  • Dickson, Dennis W.|||0000-0001-7189-7917
  • Graff-Radford, Neill R.
  • Knopman, David
  • Rademakers, Rosa
  • Lemstra, Afina W.|||0000-0002-8933-3260
  • Pijnenburg, Yolande|||0000-0003-2464-1905
  • Scheltens, Philip|||0000-0002-1046-6408
  • Gasser, Thomas|||0000-0003-4882-2647
  • Chinnery, Patrick F.
  • Hemmer, Bernhard|||0000-0001-5985-6784
  • Huisman, Martijn A.
  • Troncoso, Juan
  • Moreno, Fermin|||0000-0001-5200-3164
  • Nohr, Ellen A.
  • Sørensen, Thorkild I. A.|||0000-0003-4821-430X
  • Heutink, Peter|||0000-0001-5218-1737
  • Sánchez-Juan, Pascual|||0000-0002-6081-8037
  • Posthuma, Danielle|||0000-0001-7582-2365
  • Clarimón, Jordi|||0000-0002-6824-6942
  • Christensen, Kaare|||0000-0002-5429-5292
  • Ertekin-Taner, Nilüfer
  • Scholz, Sonja|||0000-0002-6623-0429
  • Ramirez, Alfredo|||0000-0003-4991-763X
  • Ruiz Laza, Agustín|||0000-0003-2633-2495
  • Slagboom, Eline
  • van der Flier, Wiesje M.|||0000-0001-8766-6224
  • Holstege, Henne|||0000-0002-7688-3087
The genetic variant rs72824905-G (minor allele) in the PLCG2 gene was previously associated with a reduced Alzheimer's disease risk (AD). The role of PLCG2 in immune system signaling suggests it may also protect against other neurodegenerative diseases and possibly associates with longevity. We studied the effect of the rs72824905-G on seven neurodegenerative diseases and longevity, using 53,627 patients, 3,516 long-lived individuals and 149,290 study-matched controls. We replicated the association of rs72824905-G with reduced AD risk and we found an association with reduced risk of dementia with Lewy bodies (DLB) and frontotemporal dementia (FTD). We did not find evidence for an effect on Parkinson's disease (PD), amyotrophic lateral sclerosis (ALS) and multiple sclerosis (MS) risks, despite adequate sample sizes. Conversely, the rs72824905-G allele was associated with increased likelihood of longevity. By-proxy analyses in the UK Biobank supported the associations with both dementia and longevity. Concluding, rs72824905-G has a protective effect against multiple neurodegenerative diseases indicating shared aspects of disease etiology. Our findings merit studying the PLCγ2 pathway as drug-target.
Dipòsit Digital de Documents de la UAB
Publicación Artículo científico (JournalArticle)

Differential levels of Neurofilament Light protein in cerebrospinal fluid in patients with a wide range of neurodegenerative disorders

  • Delaby, Constance|||0000-0002-8606-6814
  • Alcolea, Daniel|||0000-0002-3819-3245
  • Carmona Iragui, Maria|||0000-0001-6914-2339
  • Illán-Gala, Ignacio|||0000-0002-5418-2052
  • Morenas-Rodríguez, Estrella|||0000-0002-7591-6051
  • Barroeta, Isabel|||0000-0003-2764-7923
  • Altuna-Azkargorta, Miren|||0000-0001-9709-5314
  • Estellés, Teresa
  • Santos Santos, Miguel Ángel|||0000-0003-1567-617X
  • Turon-Sans, Janina|||0000-0002-8842-4646
  • Muñoz, Lourdes
  • Ribosa-Nogué, Roser|||0000-0002-9233-4336
  • Sala Matavera, Isabel|||0000-0002-9886-4792
  • Sánchez-Saudinós, María Belén|||0000-0003-1795-1833
  • Subirana, Andrea
  • Videla Toro, Laura|||0000-0002-9748-8465
  • Benejam, Bessy|||0000-0002-6789-8615
  • Sirisi Dolcet, Sonia|||0000-0002-5366-7832
  • Lehmann, Stépánka
  • Belbin, Olivia|||0000-0002-6109-6371
  • Clarimón, Jordi|||0000-0002-6824-6942
  • Blesa, Rafael|||0000-0003-4026-2884
  • Pagonabarraga Mora, Javier|||0000-0002-3248-704X
  • Rojas-Garcia, Ricard|||0000-0003-1411-5573
  • Fortea, Juan|||0000-0002-1340-638X
  • Lleó, Alberto|||0000-0002-2568-5478
Cerebrospinal fluid (CSF) biomarkers are useful in the diagnosis and the prediction of progression of several neurodegenerative diseases. Among them, CSF neurofilament light (NfL) protein has particular interest, as its levels reflect neuroaxonal degeneration, a common feature in various neurodegenerative diseases. In the present study, we analyzed NfL levels in the CSF of 535 participants of the SPIN (Sant Pau Initiative on Neurodegeneration) cohort including cognitively normal participants, patients with Alzheimer disease (AD), Down syndrome (DS), frontotemporal dementia (FTD), amyotrophic lateral sclerosis (ALS), dementia with Lewy bodies (DLB), progressive supranuclear palsy (PSP) and corticobasal syndrome (CBS). We evaluated the differences in CSF NfL accross groups and its association with other CSF biomarkers and with cognitive scales. All neurogenerative diseases showed increased levels of CSF NfL, with the highest levels in patients with ALS, FTD, CBS and PSP. Furthermore, we found an association of CSF NfL levels with cognitive impairment in patients within the AD and FTD spectrum and with AD pathology in DLB and DS patients. These results have implications for the use of NfL as a marker in neurodegenerative diseases.